Theratechnologies (NASDAQ:THTX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Theratechnologies (NASDAQ:THTX) issued its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03), Fidelity Earnings reports. Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. During the same period in the prior year, the business posted ($0.09) earnings per share.

THTX traded down $0.06 during midday trading on Thursday, hitting $3.51. 510 shares of the company were exchanged, compared to its average volume of 310,056. The firm has a market capitalization of $332.45 million, a P/E ratio of -11.90 and a beta of 1.65. Theratechnologies has a 1-year low of $1.83 and a 1-year high of $4.46. The firm’s 50 day moving average price is $3.61 and its 200-day moving average price is $3.63. The company has a quick ratio of 1.74, a current ratio of 2.41 and a debt-to-equity ratio of 1.52.

THTX has been the topic of several recent analyst reports. Zacks Investment Research upgraded Theratechnologies from a “sell” rating to a “hold” rating in a research note on Wednesday, September 15th. Canaccord Genuity downgraded Theratechnologies from a “buy” rating to a “hold” rating and cut their price objective for the company from $8.00 to $3.00 in a report on Thursday, July 29th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.17.

An institutional investor recently raised its position in Theratechnologies stock. Morgan Stanley lifted its holdings in Theratechnologies Inc. (NASDAQ:THTX) by 143.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,716,512 shares of the company’s stock after acquiring an additional 1,012,777 shares during the period. Morgan Stanley owned approximately 1.81% of Theratechnologies worth $6,660,000 as of its most recent filing with the Securities and Exchange Commission. 19.29% of the stock is currently owned by institutional investors.

Theratechnologies Company Profile

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Featured Story: Growth Stocks

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.